TGFBR-2 KO CD70 CAR NK cell therapy (The University Of Texas MD Anderson Cancer Center)

N/A

Report date: 2025/07/22 20:00:10

Base Information

Drug NameTGFBR-2 KO CD70 CAR NK cell therapy (The University Of Texas MD Anderson Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionCD70 antigen modulatorsTransforming growth factor beta receptor 2 modulatorsNatural killer cell replacements

TargetsCD70 antigenTransforming growth factor beta receptor 2

Therapy Area/IndicationsAdenocarcinoma, Clear Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center

Inactive CompaniesN/A

Active IndicationsAdenocarcinoma, Clear Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A